FLNA: A Potential Drug Target and Biomarker for Various Diseases

Target Name: FLNA

NCBI ID: G2316

FLNA

FLNA: A Potential Drug Target and Biomarker for Various Diseases

FLNA (fusin-L subunit alpha) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the protein family FBN1, which is characterized by the presence of a fusin- like domain and a subunit alpha helix.

FLNA has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Its unique structure and expression patterns have made it an attractive target for researchers to study, and its functions have led to a number of publications and research studies.

One of the key functions of FLNA is its role in cell adhesion and migration. FLNA is a cell adhesion molecule that is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and function. It is also involved in the migration of cells, both in the development of tissue repair and in the regulation of tissue homeostasis.

FLNA has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that FLNA is overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. This overexpression has been shown to contribute to the development of cancer-related traits, such as increased invasiveness and metastasis.

Another function of FLNA is its role in neurodegenerative diseases. As we age, the brain and nervous system are exposed to a number of environmental and genetic stressors that can lead to the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. FLNA has been shown to be involved in the development and progression of these diseases, and its overexpression has been linked to the worsening of neurodegenerative symptoms.

FLNA has also been identified as a potential biomarker for cardiovascular disease. The cardiovascular system is a critical organ that is responsible for delivering oxygen and nutrients to the body's cells and for removing waste products. FLNA has been shown to be involved in the regulation of cardiovascular function, and its expression has been linked to the development and progression of cardiovascular disease.

In conclusion, FLNA is a protein that is expressed in various tissues throughout the body and has been identified as a potential drug target and biomarker for a variety of diseases. Its unique structure and functions make it an attractive target for research and development of new treatments . Further studies are needed to fully understand its role in the development and progression of various diseases and to develop effective strategies for its targeting and use as a biomarker.

Protein Name: Filamin A

Functions: Promotes orthogonal branching of actin filaments and links actin filaments to membrane glycoproteins. Anchors various transmembrane proteins to the actin cytoskeleton and serves as a scaffold for a wide range of cytoplasmic signaling proteins. Interaction with FLNB may allow neuroblast migration from the ventricular zone into the cortical plate. Tethers cell surface-localized furin, modulates its rate of internalization and directs its intracellular trafficking (By similarity). Involved in ciliogenesis. Plays a role in cell-cell contacts and adherens junctions during the development of blood vessels, heart and brain organs. Plays a role in platelets morphology through interaction with SYK that regulates ITAM- and ITAM-like-containing receptor signaling, resulting in by platelet cytoskeleton organization maintenance (By similarity). During the axon guidance process, required for growth cone collapse induced by SEMA3A-mediated stimulation of neurons (PubMed:25358863)

The "FLNA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FLNA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets